Skip to main navigation Skip to search Skip to main content

Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury

Jin Zheng, Hui Ching Michelle Lee, Mohamad Mukmin Bin Sattar, Yu Huang, Jin-Song Bian

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

Abstract

Doxorubicin-induced generation of reactive oxygen species is a leading cause of cardiomyopathy, the major side-effect limiting the clinical use of this anti-cancer drug. Epigallocatechin-3-gallate (EGCG), a main catechin in green tea that possesses a strong antioxidant property. This study aims to investigate whether EGCG can protect cardiac myocytes against doxorubicin-induced myocyte injury. Myocyte viability was measured with an MTT assay. Reactive oxygen species were measured with fluorescent dye 2′,7′- dichlorodihydrofluorescein diacetate. Myocyte shortening and intracellular Ca2+ levels were determined with a spectrofluorometer connected to a video edge detection system. EGCG concentration-dependently increased cell viability and inhibited the generation of reactive oxygen species in doxorubicin-treated myocytes. Doxorubicin significantly decreased the amplitudes of cell shortening, the maximum velocity of cell contraction (+ dl/dt) and relaxation (- dl/dt) in electrically-stimulated myocytes in the presence or absence of isoprenaline, which was attenuated by EGCG. The present data suggest that EGCG may protect myocytes against oxidative stress-induced cellular injury in doxorubicin-treated cardiac myocytes. The effect of EGCG on Ca2+ handling was also examined. EGCG increased the amplitudes of both electrically- and caffeine-induced Ca2+ transients in doxorubicin-treated myocytes, suggesting that EGCG may reverse doxorubicin-induced intracellular Ca 2+ depletion in the sarcoplasmic reticulum. We found in the present study that EGCG may protect heart against doxorubicin-induced myocyte injury by improving Ca2+ handling through scavenging reactive oxygen species. Our results imply that EGCG may be used together with doxorubicin to minimize its cardiac toxic effects. © 2010 Elsevier B.V.
Original languageEnglish
Pages (from-to)82-88
JournalEuropean Journal of Pharmacology
Volume652
Issue number1-3
DOIs
Publication statusPublished - 10 Feb 2011
Externally publishedYes

Bibliographical note

Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Keywords

  • Cardiomyopathy
  • Cardioprotective
  • Doxorubicin
  • EGCG
  • Reactive oxygen species

Fingerprint

Dive into the research topics of 'Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury'. Together they form a unique fingerprint.

Cite this